Association between Initial Oral Therapy and Outcomes in Systemic Sclerosis-Related Pulmonary Arterial Hypertension

Arthritis and Rheumatology

Volumn 68, Issue 3, 2016, Pages 740-748

  Lammi, Matthew R ^a   Mathai, Stephen C ^b   Saketkoo, Lesley Ann ^c   Domsic, Robyn T ^d   Bojanowski, Christine ^a,g   Furst, Daniel E ^e   Steen, Virginia D ^f  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; CARBON MONOXIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; SILDENAFIL; TADALAFIL;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; LUNG DIFFUSION CAPACITY; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; HYPERTENSION, PULMONARY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; TIME FACTOR; VASCULAR RESISTANCE;

ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 84963823074     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39478     Document Type: Article

References (38)

1. Chaisson NF, Hassoun PM., Systemic sclerosis-associated pulmonary arterial hypertension [review]. Chest 2013; 144: 1346-56.
2. Steen VD, Medsger TA., Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
3. Fisher MR, Mathai SC, Champion HC, Girgis RE, Houston-Harris T, Hummers L, et al., Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-50.
4. Avouac J, Wipff J, Kahan A, Allanore Y., Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials. Ann Rheum Dis 2008; 67: 808-14.
5. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A., A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
6. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al., Updated classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 Suppl 25: 34-41.
7. Denton CP, Humbert M, Rubin L, Black CM., Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006; 65: 1336-40.
8. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al, for the SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-18.
9. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galie N, et al, and the SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34: 2417-22.
10. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al, on behalf of the Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension [published erratum appears in Circulation 2011;124:e279]. Circulation 2009; 119: 2894-903.
11. Girgis RE, Frost AE, Hill NS, Horn EM, Langleben D, McLaughlin VV, et al., Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007; 66: 1467-72.
12. Hinchcliff M, Fischer A, Schiopu E, Steen VD., Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38: 2172-9.
13. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al., Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D42-50.
14. Dafni U., Landmark analysis at the 25-year landmark point [review]. Circ Cardiovasc Qual Outcomes 2011; 4: 363-71.
15. Medsger T., Classification. In:, Clements PJ, Furst D, editors. Systemic sclerosis. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2004. p. 17-28.
16. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little Brown; 1994. p. 253-6.
17. Sauerbrei W., The use of resampling methods to simplify regression models in medical statistics. Appl Stat 1999; 48: 313-29.
18. Hair JF Jr, Anderson RE, Tatham RL, Black WC., Multivariate data analysis. 3rd ed. New York: Macmillan; 1995.
19. Lammi MR, Saketkoo LA, Mathai SC, Domsic RT, Bojanowski CM, Steen VD, et al, and PHAROS Investigators. Initial therapy with an endothelin receptor antagonist is associated with worse outcomes in patients with systemic sclerosis and pulmonary arterial hypertension: observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort [abstract]. Arthritis Rheumatol 2014; 66 Suppl: S738-9.
20. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al., Survival in patients with idiopathic, familial, and anorexigen associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-63.
21. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al., Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-72.
22. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers L, Boyce D, et al., Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 252-60.
23. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al., Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383-94.
24. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al., Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma registry. Arthritis Care Res (Hoboken) 2014; 66: 489-95.
25. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al, for the AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-44.
26. Kedzierski RM, Yanagisawa M., Endothelin system: the double-edged sword in health and disease [review]. Annu Rev Pharmacol Toxicol 2001; 41: 851-76.
27. B receptor in cardiovascular physiology and pathophysiology [review]. Pharmacol Ther 2002; 95: 221-38.
28. Bohm F, Pernow J, Lindstrom J, Ahlborg G., ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 2003; 104: 143-51.
29. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, et al., Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist [review]. J Pharmacol Exp Ther 2008; 327: 736-45.
30. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-100.
31. Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al, for the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Studies Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008; 117: 3010-9.
32. Oudiz RJ, Galie N, Olschewski H, Torres F, Frost A, Ghofrani HA, et al, ARIES Study Group. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: 1971-81.
33. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al., Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-22.
34. Wilkins MR, Paul GA, Strange JW, Tunariu N, Gin-Sing W, Banya WA, et al., Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171: 1292-7.
35. Sandoval J, Bauerle O, Palomar A, Gomez A, Martinez-Guerra ML, Beltran M, et al., Survival in primary pulmonary hypertension: validation of a prognostic equation. Circulation 1994; 89: 1733-44.
36. Sztrymf B, Souza R, Bertoletti L, Jais X, Sitbon O, Price LC, et al., Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J 2010; 35: 1286-93.
37. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M, et al., Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-8.
38. D'Alonzo GE, Barst RJ, Ayres SM, Borgofsky EH, Brundage BH, Detre KM, et al., Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.